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ABSTRACT 
Ataxia-telangiectasia (AT) is a neurodegenerative disorder characterized by ataxia, telangiectasia, and 
immunodeficiency. An increased risk of malignancies and respiratory diseases dramatically reduce 
life expectancy. To better counsel families, develop individual follow-up programs, and select 
patients for therapeutic trials, more knowledge is needed on factors influencing survival. This 
retrospective cohort study of 61 AT patients shows that classical AT patients had a shorter survival 
than variant patients (HR 5.9, 95%CI 2.0-17.7), especially once a malignancy was diagnosed (HR 2.5, 
95%CI 1.1-5.5, compared to classical AT patients without malignancy). Patients with the hyper IgM 
phenotype with hypogammaglobulinemia (AT-HIGM) and patients with an IgG2 deficiency showed 
decreased survival compared to patients with normal IgG (HR 9.2, 95%CI 3.2-26.5) and patients with 
normal IgG2 levels (HR 7.8, 95%CI 1.7-36.2), respectively. If high risk treatment trials will become 
available for AT, those patients with factors indicating the poorest prognosis might be considered for 
inclusion first.  
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Highlights:  
 More knowledge is needed on factors influencing survival in patients with AT; 
 Patients with AT-HIGM have a severely reduced life expectancy compared to patients with 
normal IgG  levels; 
 AT-HIGM patients may be candidates for future high risk therapeutic trials.  
Key words: ataxia telangiectasia, survival, hyper IGM phenotype, primary immunodeficiency  
Abbreviations: 
95%CI: 95% Confidence interval  
AT: Ataxia-telangiectasia  
ATM: Ataxia telangiectasia mutated  
AT-HIGM: Hyper IgM phenotype with hypogammaglobulinemia 
HR: Hazard ratio  
OR: Odds ratio 
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1. INTRODUCTION 
Ataxia-telangiectasia (AT; OMIM 208900) is an autosomal recessive neurodegenerative disease 
caused by mutations in the ataxia telangiectasia mutated (ATM) gene[1]. The ATM gene codes for 
ATM kinase, which plays a role in cell cycle control and DNA repair[2]. Over 400 ATM mutations have 
been described so far[3]. AT is characterized by cerebellar ataxia, oculocutaneous telangiectasia, 
increased radiosensitivity, growth retardation, predisposition to malignancies and diabetes mellitus 
type II, and a primary cellular and humoral immunodeficiency causing recurrent sinopulmonary 
infections[4]. The immunodeficiency is caused by impaired double-strand break repair processes, 
such as V(D)J recombination[5] and class-switch recombination[6, 7], and features a reduced number 
of circulating T-cells (in particular CD3+CD4+CD45RA+ naïve T-cells) and B-cells, frequently causing 
decreased or absent serum IgA and IgG2[8, 9]. An estimated 10% of AT patients have decreased IgA 
and IgG levels with normal to increased IgM levels[10], designated as ‘hyper IgM phenotype with 
hypogammaglobulinemia’ (AT-HIGM). AT is incurable and patients have a reduced life expectancy 
due to cancer, pulmonary disease, and infections[11].  
The clinical spectrum of AT is variable[12] with residual kinase activity and the related type of 
ATM mutation contributing to the life expectancy[11, 13]. Variant AT patients have a milder clinical 
phenotype and a longer lifespan compared to classical AT patients[11-13]; their longer life 
expectancy may be attributed to less severe immunodeficiency[8, 9] and delayed onset of 
cancer[11]. 
Much is known about the pathogenesis of AT but knowledge of factors predicting survival is 
lacking. To further individualize follow-up programs for AT patients, and eventually select eligible 
patients for future therapeutic trials, better knowledge on factors that contribute to survival is 
needed.   
The aim of this study was to identify such factors in both classical and variant AT.  
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2. MATERIAL AND METHODS 
2.1. Ascertainment of study cohort  
Data were retrospectively collected from Dutch and Icelandic cohorts of AT patients. For patients 
previously described by Verhagen et al.[13], the follow-up period was extended by six years. The 
clinical diagnosis of AT was confirmed by the identification of pathogenic ATM mutations in all 
subjects. The ATM mutation analysis and the measurements of ATM protein and ATM kinase activity 
in patients with available lymphoblast cell lines were performed using previously described methods 
[14, 15]. Data on age, gender, nationality, age and cause of death, immunoglobulin levels of IgA, IgG, 
IgG2, IgM, and lymphocyte subsets (all pre-treatment, in case of immunoglobulin replacement 
therapy), and presence of cancer were collected from the cohort database or the medical records of 
the patient’s primary hospital. Immunoglobulin plasma levels and lymphocyte subsets were assessed 
using methods previously described [16], and compared to age-related reference values [17, 18]. The 
follow-up period was defined as starting at birth and continuing until death or August 31, 2014, 
whichever came first. Patients lost to follow-up were excluded from the study. This study was 
approved by the Regional Committee on Research involving Human Subjects Arnhem-Nijmegen. 
2.2. Patient definitions 
The patients were classified into four groups, based on the presence of ATM protein and ATM kinase 
activity. The classical AT patients comprised patients without detectable ATM protein (group 1), 
patients with ATM protein but without ATM kinase activity (group 2), and patients with missing data 
on ATM protein and ATM kinase activity, but with clinical phenotypes similar to those in groups 1 and 
2 (Supplement 1) (group 3). Group 4 consisted of variant AT patients with residual kinase activity. 
Patients with decreased IgG and IgA levels but with normal or elevated IgM levels at the time of 
diagnosis were classified as AT-HIGM (group 1a), and those with normal total IgG levels as group 1b.  
2.3. Literature search  
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To supplement the data from our cohort, we searched all available literature for reports on patients 
with AT-HIGM. We searched all available literature until January 2016 through the electronic 
databases PubMed, EMBASE, the Cochrane Library, and Web of Science. For all patients that were 
alive at time of publication, the first authors of the papers were contacted for additional information 
on survival.  
2.4. Statistical analysis  
Using IBM SPSS statistics 22.0 for Windows (IBM SPSS Inc., Chicago, IL, USA), we performed 
descriptive statistics and logistic regression analyses to calculate odds ratios (OR) with 95% 
confidence intervals (95%CI) for associations between immunoglobulin deficiencies and AT 
phenotypes. Differences in survival between groups were assessed using Cox proportional hazard 
models to calculate hazard ratios (HR) with 95%CIs, which are more informative than p-values. The 
OR and HR represents the strength of the association, while the 95%CI shows the imprecision in the 
estimate. Confidence intervals that do not or only just include the null value (OR/HR=1) are indicative 
of statistically significant and/or noticeable results. To avoid interpretation problems because of low 
numbers in multivariable analyses, the HRs were only adjusted for gender. In sensitivity analyses, 
patients with <10 years of follow-up (n=11, al classical AT) were excluded. GraphPad Prism v5.03 was 
used to display Kaplan Meier survival probability curves from birth through August 2014, at which 
point patients were censored if the event (e.g. death or malignancy) had not yet occurred.  
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3. RESULTS  
3.1. Cohort description 
The total cohort consisted of 63 patients. Two patients that were lost to follow-up were excluded 
from the analysis, leading to inclusion of 61 AT patients (29 male and 32 female patients), divided 
into 48 patients with classical AT (17 in group 1, 19 in group 2, and 12 in group 3) and 13 patients 
with variant AT (Table 1 and Figure 1a). In total, 50 of these patients were previously described by 
our research group[13] in a genotype-phenotype correlation study, while 27 patients were also 
described in other reports[8, 19-23].  
The ages of the patients ranged from 4 to 56 years. At the end of follow-up, 32 patients were 
deceased and 29 were alive. In the latter group, 16 patients, all with classical AT, were still under 30 
years of age (Figure 1b). Among 48 classical AT patients, only six patients (12.5%) survived beyond 30 
years of age: two in group 1 and four in group 2. The two patients from group 1 died at ages 40 and 
54 from malignancies, whereas the other four patients were 35, 32, 49, and 50 years old and still 
alive at the end of follow-up. Among the variant AT patients, all but one survived beyond 30 years of 
age. Fifty different mutations in 33 exons were found in the cohort, while 19 patients had 
homozygous ATM mutations (Table 1).                  
IgG2 subclass plasma levels were measured in 46 out of the 61 patients (38 with classical AT and 8 
with variant AT), of whom 29 had an IgG2 deficiency. Only one IgG2 deficiency was observed in a 
variant AT patient. IgA levels were measured in 53 patients, of whom 25 had an IgA deficiency. None 
of the variant AT patients had IgA deficiency. IgG and IgM levels were normal in the majority of 
patients, but 7 classical AT patients without expression of ATM protein had AT-HIGM (group 1a). 
Among the patients in this group with normal IgG levels (group 1b), 78% were IgG2 deficient 
compared to 60% in group 2 (OR 2.3, 95%CI 0.4-15.3), with IgA deficiency in 60% of patients in group 
1b versus 41% in group 2 (OR 3.6, 95%CI 0.8-17.0). The lymphocyte subsets of patients from group 1a 
(AT-HIGM group) are shown in Supplement 2. 
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Table 1: Features of 61 AT patients from the Netherlands and Iceland.  
 No  Sex Ethni
- 
city# 
Age 
or age 
at 
death 
ATM mutations Immunoglobulin levels Cancer type Cause of death Immuno-
globulin 
therapy 
Antibiotic 
prophylaxis 
Allele 1 Allele 2 IgG IgG2 IgA 
 
IgM 
Group 1a 
 
Classical AT 
patients, 
ATM 
protein 
absent, AT-
HIGM 
phenotype 
1 M  NL 13† exon 19-61 c.2467+1551 
del 97kb 
exon 19-61 c.2467+1551 del 
97kb 
D D D N Lymphoma  Malignancy Yes Yes 
2a F  AF 9† exon 37 c.5188C>T exon 37 c.5188C>T D D D N - Respiratory 
failure  
Yes x 
2b F  AF 12† exon 37 c.5188C>T exon 37 c.5188C>T D D D N - Respiratory 
failure  
Yes  Yes  
2c M   AF 10† exon 37 c.5188C>T exon 37 c.5188C>T D D D N Hepatocellular 
carcinoma 
Malignancy Yes x 
3 F  MO 14† exon 21 c.2921+5G>A exon 21 c.2921+5G>A D D D N - Respiratory 
failure  
Yes Yes 
4* F  BE 9† exon 12 
c.1563_1564delAG 
exon 39 c.5515 C>T D D D N Lymphoma  Malignancy Yes  Yes  
5 F  IC 12† exon 19 c.2554C>T exon 19 c.2554C>T D D D N - Respiratory 
failure  
Yes  Yes  
Group 1b 
 
Classical AT 
patients, 
ATM 
protein 
absent  
6 M  NL 20 exon 9 c.790_790delT exon 12 c.1563_1564delAG N D D N - - Yes  Yes  
7 F  NL 22† exon 
10 c.1027_1030delGAAA  
exon 13 c.1660_1660delA N D D N B-cell non-
Hodgkin 
lymphoma  
Urinary tract 
bleeding§  
Yes  No  
8 F  TR 9† exon 12 
c.1514_1515delTT 
exon 12 c.1514_1515delTT ↑ x N ↑ Hodgkin 
lymphoma  
Malignancy  Yes  Yes  
9a F  NL 21† exon 12 
c.1563_1564delAG 
exon 39 c.5515 C>T N N N N - Not noted  No  No  
9b F  NL 10† exon 12 
c.1563_1564delAG 
exon 39 c.5515 C>T N D N N B-cell lymphoma Malignancy  No  No  
10 M  TR 12 exon 43 c.6082 C>T exon 43 c.6082 C>T N D D N - - No  Yes  
11 µ M  NL  40† exon 12 c.1563_ 
1564delGA 
exon 23 c.3078 G>T D-N D D N-↑ B-cell non-
Hodgkin 
lymphoma 
Malignancy  Tempo-
rarily  
No  
12 M  AN 22 exon 27 c.3741-1G>C  exon 37 c.5197G>C  N D D N - - Tempo-
rarily  
No  
13* M  NL 54† exon 6 c.331+5G>A exon 29 c.4040delT N N N ↑ Prostate cancer 
 
Malignancy No  No  
14* M  IC 15 exon 6 c.309C>G exon 12 c.1369C>T N D D N - - No  No  
Group 2 
 
Classical AT 
patients, 
15a F  IR 9† exon 61 c.8633T>G Unidentified  x x x x Hodgkin 
lymphoma  
Malignancy  No  Yes  
15b M  IR 26† exon 61 c.8633T>G Unidentified N-D D N N Hodgkin 
lymphoma 
Malignancy  Yes  Yes  
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ATM 
protein 
present, no 
kinase 
activity 
16 F   NL 13 exon 48 c.6629delA exon 60 c.8578_8580delTCT N N D N - - Yes  Yes  
17a M  NL 15 exon 55 
c.7875_7876delTGinsGC 
exon 55 
c.7875_7876delTGinsGC 
N D N N - - No  Yes  
17b 
µ 
F  NL 4† exon 55 
c.7875_7876delTGinsGC 
exon 55 
c.7875_7876delTGinsGC 
D-N D D-N 
 
N Acute 
lymphoblastic 
leukemia  
Pulmonary 
hypertension§ 
Tempo-
rarily 
Yes  
18a  F  NL 22† exon 55 
c.7875_7876delTGinsGC 
exon 55 
c.7875_7876delTGinsGC 
N-D D N N - Respiratory 
failure  
Yes  Yes  
18b M  NL 10† exon 55 
c.7875_7876delTGinsGC 
exon 55 
c.7875_7876delTGinsGC 
N D D N Lymphoma  Respiratory 
failure/ 
malignancy 
No  No  
19 F  NL 27† exon 55 
c.7875_7876delTGinsGC 
exon 60 c.8578_8580delTCT N-↑ N D N Breast cancer  Respiratory 
failure/ 
malignancy 
x x 
20a M  NL 26† exon 41 c.5762-2 A>T Unidentified N D N N - Respiratory 
failure 
No  Yes 
20b M  NL 14† exon 41 c.5762-2 A>T Unidentified N x D N - Respiratory 
failure  
No  Yes  
21 M  NL 21 exon 6 c.331+5G>A exon 55 
c.7875_7876delTGinsGC 
N N D N - - No  No  
22 F  TR 22 exon 26 c.3576 G>A exon 26 c.3576 G>A N N N N - - No  Yes  
23a F  TR 24† exon 26 c.3576G>A exon 26 c.3576G>A x x x x Dermatofibro-
sarcoma 
protuberans  
Resuscitation 
needed for 
unknown cause 
No  No  
23b M  TR 35 exon 26 c.3576G>A exon 26 c.3576G>A N D ↑ N Dermatofibro-
sarcoma 
protuberans 
- No  No  
24a* M  NL 32 exon 29 c.4109+5G>A exon 55 
c.7875_7876delTGinsGC 
N D D N - - No  No  
24b* F  NL 28 exon 29 c.4109+5G>A  exon 55 
c.7875_7876delTGinsGC 
↑ N ↑ ↑ - - No  No  
25*
∞ 
F  NL 9 exon 14. c1898+2T>G exon 32 c.4477C>G D D N N - - Yes   No  
26* M  TR 7 exon 48 c.6679C>T exon 48 c.6679C>T N N D N - - No  No  
27* M  IC  7  exon 12 c.1369 exon 65 c.9139C>T N x N N - - No  x 
Group 3 
 
Classical AT 
patients, 
no data on 
ATM 
protein and 
28  M  TN 17† exon 14 c.1810 C>T exon 47 c.6482 G>C ↑ x N ↑ Non-Hodgkin 
lymphoma 
Not noted x x 
29  F NL 25 exon 17 c.2376+1G>A exon 55 
c.7875_7876delTGinsGC 
x x x x - - x x 
30  M  KR / 
GE  
9† exon 12 
c.1563_1564delAG 
exon 53 c.7542T>G N D D ↑ T-cell lymphoma  Malignancy No  No  
31  M  TR 15† exon 58 c.8264dupA exon 58 c.8264dupA N x N N T-cell acute Asystole after No  No  
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kinase 
activity 
lymphoblastic 
leukemia 
extubation§  
32  F  NL 15† exon 9 
c.738_739delCTinsA 
exon 55 
c.7875_7876delTGinsGC 
N x D N B-cell lymphoma  Respiratory 
failure/ 
malignancy 
No  Yes  
33  M  NL 18 exon 7 c.484 C>T exon 14 c.1898+2 T>G N D N N Lymphoma  - Yes  Yes  
34* F  NL 10† exon 65 c.9019 G>T Unidentified N D D N - Respiratory 
failure  
Yes  Yes  
35a  F  SR 49 exon 20 c.2839-
579_2839-576del4 
exon 31 c.4396 C>T ↑ N ↑ N - - No  x 
35b  F  SR 50 exon 20 c.2839-
579_2839-576del4 
exon 31 c.4396 C>T ↑ x ↑ ↑ - - No  x 
36 M  NL 17† exon 20 c.2662 G>T exon 48 c.6679 C>T N D N N B-cell non-
Hodgkin 
lymphoma 
Malignancy x No 
37* F  SR 9 exon 19 c.2620G>T exon 31 c.4344_4345delAT N D D ↑ - - No  Yes 
38* M  NL 4 exon 12 
c.1564_1565delGA 
exon 55 
c.7875_7876delTGinsGC 
N N D N - - No  x 
Group 4 
 
Variant AT 
patients, 
ATM 
protein 
present, 
residual 
kinase 
activity 
39 F  NL 54 exon 7 c.496+5G>A exon 55 
c.7875_7876delTGinsGC 
x x x x - - No No 
40 F  NL 47† exon 57 c.8147T>C exon 12 
c.1391_1395delTGTGT 
 
N x N x Breast cancer, 
chronic myeloid 
leukemia 
Malignancy No  No  
41 F  NL 43 exon 57 c.8147T>C Unidentified N N N N Breast cancer  - No No 
42 F  NL 56 exon 9 c.717_720delCCTC exon 57 c.8147 T>C x x x x - - No  No  
43 F  NL 40 exon 42 c.5932 G>T exon 57 c.8147 T>C N N N N - - No No 
44a  F  NL 39 exon 21 c. 2909 T>G exon 49 c.6908dupA N N N N - - No  No  
44b  M  NL 23† exon 21 c. 2909 T>G exon 49 c.6908dupA x x x x Ectopic pituitary 
tumor 
Malignancy  No No 
45a  M  NL 39 exon 6  c.331+5G>A exon 6  c.331+5G>A N N N N - - No  No  
45b  F  NL 42 exon 6  c.331+5G>A exon 6  c.331+5G>A N D N N - - No No 
46 F  NL 56 exon 22 c.2922-1G>A exon 57 c.8147 T>C N N N N - - No  No  
47a M  NL 48† exon 23 c.3136 C>T exon 53 c.7622 T>G N N N N Pancreatic 
cancer 
Malignancy  No No 
47b  M  NL 51 exon 23 c.3136 C>T exon 53 c.7622 T>G N N N N - - No  No  
47c  M  NL 51† exon 23 c.3136 C>T exon 53 c.7622 T>G x x x x Acute 
lymphoblastic 
leukemia 
Malignancy  No  No  
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* Patient was not described before by Verhagen et al. (n=11); 
a-b-c Patients are siblings; 
† Patient is deceased; 
# NL = Dutch; AF = Afghan; MO = Moroccan; BE = Belgian; IC = Icelandic; TR = Turkish; AN = Antillean; IR = Iranian; TN = Tunisian; KO = Korean; GE = German; SR = Surinamese; 
D= deficient; N= normal; ↓= decreased (compared to age-related reference values [17, 18]); x= not measured or unknown; 
§ Cause of death was a complication of malignancy treatment; 
µ Patient 17b was excluded from our IgA immunoglobulin analysis since IgA levels were variable during life. Patients 11, 15b, and 18a were excluded from the AT-HIGM group since IgG levels were variable during life. 
∞ Patient 25 was excluded from group 1a (AT-HIGM) since she had normal IgA levels and her IgG level increased to normal after only two gifts of immunoglobulin replacement therapy. 
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Figure 1: Flow charts of the cohort. 
1a. Flow chart of groups based on ATM kinase activity, ATM protein detectability, and HIGM status. 
 
 
1b. Flow chart of cohort based on survival. 
Variant (13) 
Classical (48) 
Patients (61) 
ATM + (19) 
No ATM (17) 
HIGM (7) 
No HIGM (10) 
No data on 
ATM (12) 
Group 4 
Group 2 
Group 3 
Group 1a 
Group 1b 
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
14 
 
 
 
 
Deceased 
(32) 
Alive (29) 
Patients (61) 
< 30 yrs (16) 
> 30 yrs (13) 
> 30 yrs (5) 
< 30 yrs (27) 
Classical (4) 
Variant (9) 
Classical (16) 
Variant (0) 
Classical (2) 
Variant (3) 
Classical (26) 
Variant (1) 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
15 
 
3.2. Survival analyses 
As shown in Figure 2, patients with classical AT generally died at a much younger age than variant 
AT patients. The corresponding hazard ratio for classical AT compared to variant AT was 5.9 (95% CI 
2.0-17.7). Only very slight differences in HR were observed when gender was included as co-variable 
and after exclusion of AT-HIGM patients or patients with less than 10 years of follow-up (Supplement 
3).  
Classical AT patients without detectable ATM protein (group 1) seemed to have a slightly lower 
chance of survival compared to patients with ATM protein without kinase activity (group 2) (HR 1.8, 
95%CI 0.7-4.4; HR adjusted for gender (HRgender 2.2, 95%CI 0.9-5.7)) (Supplements 3 and 4). When 
group 1a was excluded from the analysis, patients without detectable ATM protein (group 1b) and 
patients with ATM protein without kinase activity (group 2) did not differ in survival (HR 0.9, 95% CI 
0.3-3.0).  
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Figure 2: Survival of patients with classical (group 1,2,3) and variant (group 4) AT  
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Censored* 0 5 11 16 18 20 
Variant At risk 13 13 13 12 9 5 
Deceased  0 0 0 1 1 3 
Censored * 0 0 0 0 3 5 
* Censored patients are patients that were alive in this age category at the end of follow-up. Differences in number of patients at risk can 
be explained by deaths and censored patients. Deceased and censored numbers are cumulative. 
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3.3. Malignancy  
Among the classical AT patients, 21 (44%) had a malignancy compared to 5 patients (38%) in the 
variant group, with a median age at first diagnosis of 15 (range 4-52) and 42 (range 23-51), 
respectively. Of the 21 classical AT patients with a malignancy, 16 had a hematological malignancy, 
mostly lymphomas (n=14), and 19 patients died: 17 (81%) due to their malignancy and two from 
unknown causes (Table 1). Of these 19 patients, 17 died within one year after diagnosis. In the 
variant group, all five cancers developed in adulthood and four patients died of their malignancy: two 
of leukemia at ages 47 and 51 and two of solid tumors at ages 23 and 48 (Figure 3 and Supplement 
5).  
AT patients with a malignancy showed reduced survival compared to patients without a malignancy 
(HR 3.7, 95%CI 1.7-8.1), especially when patients with the AT-HIGM phenotype, who had an overall 
poorer survival, were excluded (HR 5.9, 95%CI 2.2-15.7) (Supplement 3). The corresponding HR when 
having a malignancy was 2.5 (95%CI 1.1-5.5) for the classical group, but could not be calculated for 
the variant group due to low numbers. Adjustment for gender and exclusion of patients with <10 
years of follow-up slightly increased or decreased the HRs, respectively. Classical AT patients without 
a malignancy and variant AT patients with a malignancy had a similar overall chance of survival (HR 
1.1, 95%CI 0.3-3.8).  
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Figure 3: Survival of AT patients with and without malignancy (in classical and variant patient groups) 
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* Censored patients are patients that were alive in this age category at the end of follow-up. Differences in number of patients at risk can 
be explained by deaths and censored patients. Deceased and censored numbers are cumulative. 
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3.4. Immunology 
3.4.1. IgG2 deficiency 
AT patients with an IgG2 deficiency had greatly reduced survival compared to patients with normal 
IgG2 levels (HR 10.2, 95%CI 2.3-45.0), even when the analyses were restricted to classical AT patients 
(HR 5.3, 95%CI 1.2-23.5). With adjustment for gender, both of these HRs increased to 13, as more 
female patients with IgG2 deficiencies died and at a younger age compared to male patients 
(Supplement 3). When the AT-HIGM phenotype was excluded in order to prevent bias, the HRs were 
7.8 (95%CI 1.7-36.2) for all IgG2 deficient patients and 4.0 (95%CI 0.9-18.7) for classical AT patients 
only (Figure 4), while the HRs adjusted for gender varied between 8.1 and 11.5, respectively. Among 
the 29 classical AT patients with IgG2 deficiency, malignancies occurred in 45% compared to 24% 
among patients with normal IgG2 levels (OR 2.6, 95%CI 0.7-10.1) and 18 patients were deceased at 
the end of follow-up: 10 (56%) died from malignancies, seven (39%) from respiratory failure, and one 
(6%) patient from either a combination or both. 
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Figure 4: Survival of classical AT patients (AT-HIGM excluded) with IgG2 deficiency and patients with 
normal IgG2 levels 
0 10 20 30 40 50 60
0
25
50
75
100
Classical AT patients
with IgG2 deficiency (n=21)
Classical AT patients
with normal IgG2 levels (n=10)
age
c
u
m
u
la
ti
v
e
 s
u
r
v
iv
a
l 
%
 
  Years 0 10 20 30 40 
Classical 
without 
AT-HIGM 
IgG2 deficiency At risk 21 14 8 3 0 
Deceased  0 5 6 10 11 
Censored * 0 2 7 8 10 
Normal IgG2  At risk 10 8 7 2 2 
Deceased  0 0 0 2 2 
Censored * 0 2 3 6 6 
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3.4.2. IgA deficiency  
None of the patients with variant AT had an IgA deficiency. The HR for classical AT patients with IgA 
deficiency was 2.2 (95%CI 0.9-5.1), compared to classical patients with normal IgA levels. When 
patients with the AT-HIGM phenotype were excluded from the analysis, the HR was 1.4 (95%CI 0.6-
3.8), indicating that survival was similar for classical AT patients with and without IgA deficieny 
(Supplement 6). Malignancies did not occur more frequently among IgA deficient patients compared 
to patients with normal IgA levels either (36% and 43%, respectively, OR 0.8, 95%CI 0.2-2.3). Both 
malignancies and respiratory failure were equally often the cause of death among IgA deficient 
patients. Patient 17b was excluded from the IgA immunoglobulin analysis since IgA levels were 
variable during life.   
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3.4.3. Hyper IgM phenotype  
The survival of AT patients with AT-HIGM (group 1a) was much worse than that of classical AT 
patients without ATM protein but with normal IgG levels (group 1b)(HR 8.0, 95%CI 1.6-40.1) (Figure 
5) or other AT patients with normal IgG levels (Supplement 3). All patients with AT-HIGM died before 
the age of 15, three from a malignancy (two of which were lymphomas), and four from respiratory 
failure. In group 1b, five patients died from a malignancy (50%) and one from an unknown cause 
(Table 1).  
In addition to the seven patients in our cohort, 15 other patients with AT-HIGM were described in 
the literature [20, 24-33]. We received additional information on survival for five patients that were 
alive at the time of publication (patients L2a, L3, L6, L7, and L14, Table 2). Eight of these 15 patients 
were reported to have died: seven between 2 and 12 years of age and one at age 24. The remaining 
patients (n=7) were alive at the time of publication, but at least three of them died after publication, 
at 10, 11, and 15 years of age.  
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Figure 5: Survival of classical AT patients with AT-HIGM phenotype (group 1a) and patients with 
normal IgG levels (group 1b)  
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 Table 2: Review of 22 patients with AT-HIGM in the present cohort and in the literature (L).  
No  M
/
F 
Age  Age at 
death 
Cause of 
death  
Phenotype (age) Diagnosis, chronological (age) Serum AFP  Mutations Siblings with AT Ref-
erence  
1* M  13 Lymphoma  Ataxia (1), telangiectasia (4), recurrent 
infections  
AT (2,5) ↑ See table 2 No  - 
2a F  9 Respiratory 
failure 
Ataxia (1), recurrent infections (1), 
telangiectasia (5) 
HIGM (1), AT (1) ↑ See table 2 Patient 2b and 2c [8, 20] 
(5-3) 
2b F  12 Respiratory 
failure  
Ataxia (1.5), recurrent infections (1.5), 
telangiectasia (6) 
HIGM (1), AT (1) ↑ See table 2 Patient 2a and 2c [8, 20] 
(5-2) 
2c M  10 Hepato-
cellular 
carcinoma 
Ataxia (3), telangiectasia (9), recurrent 
infections  
HIGM (9), AT (9) ↑ See table 2 Patient 2a and 2b [20] (5-1) 
3 F  14 Respiratory 
failure 
Ataxia (1), recurrent infections (2), 
telangiectasia (4) 
HIGM (2), AT (2) ↑ See table 2 No  [20] (2) 
4 F  9 Lymphoma  Recurrent infections, auto-immune 
heamolytic anemia, neutropenia, 
hepatosplenomegaly, lympadenopathy (1), 
unsteady gait (2), telangiectasia (4) 
Not X-linked HIGM (1), AT (2) ↑ See table 2 No  [20] (3), 
[22] 
5 F  12 Respiratory 
failure 
Recurrent infections (0.5), ataxia (1.5)  HIGM (1), AT (2) ↑ See table 2 No  [8, 20] 
(4) 
L1# F 8   Abnormal gait, lymphadenopathy, 
hepatosplenomegaly, telangiectasia (2-4), 
lymphocytic interstitial pneumonitis (5.5) 
HIGM (4.5), AT (5) ↑ 8822insAACT 
(codon 2941) 
8672 del CT (codon 
2945) 
Not noted  [33] 
L2a F  11§ Severe 
pneumonia  
Some gait disturbance (5), chronic lung 
disease  
Autosomal recessive HIGM (3), 
AT (5) 
↑ Not noted  Twin sister with 
HIGM (L2b) 
[27] 
 
L2b F  5 Hodgkin 
lymphoma  
No neurological nor cutaneous features  Autosomal recessive HIGM (3), 
AT (5) 
↑ Not noted  Twin sister with 
HIGM (L2a) 
L3 F 16§   Mild ocular telangiectasia (6) Autosomal recessive form of 
HIGM (6), AT (7) 
↑ Exon 48 c.6679 C>T, 
Exon 34 c.8484delA 
Older brother (alive) 
no HIGM 
[25] 
L4 M
  
 10 Pneumonia  Not noted  AT (1) Not tested Unknown  Younger brother 
(15, died) no HIGM 
[30] 
L5 F   24 Severe 
pneumonia  
Not noted  HIGM (4), AT (4)  ↑ Unknown  Younger sister (23, 
alive) no HIGM 
L6 F   10§ Malignant 
lymphoma  
Recurrent infections (1), cerebellar ataxia 
(2) 
HIGM (1), AT (2) ↑ exon 9 
c.842delAATT, 
homozygous  
Older sister (5, died) 
no HIGM 
L7 M
  
 15§ Multi-organ 
failure due to 
bladder 
hemorrhage 
Recurrent infections (2), cerebellar ataxia 
(5) 
HIGM (2), AT (5)  ↑ exon 10 
c.902_1065del164, 
exon 21 c.2877C>G 
Younger brother (9, 
alive) no HIGM 
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L8 F  7 Bleeding as 
side effect of 
radiotherapy 
for Wilms 
tumor  
Recurrent infections (2.5), ataxia (4), no 
telangiectasia 
Autosomal recessive form of 
HIGM (2.5), AT (5) 
↑ Exon 28 3848T>C,  
Exon 62 
8766_8767insT 
Not noted [32] 
L9 M  11 Severe 
pneumonia, 
AML  
Recurrent infections (2), ataxia and ocular 
telangiectasia (5) 
HIGM (2), AT (5) ↑  Exon 15 C 2413T,  
Exon 9 del1402-3, 
AA 
Not noted  [28, 29] 
(K) 
L10 F  8 Respiratory 
failure due to 
pneumonia  
Gait disturbance and ocular telangiectasia 
(4) 
HIGM (2), AT (4) ↑ Exon 53 c.8250C>T, 
(p.2622Ala>Val) 
homozygous  
Not noted   [24] 
L11 M 8   Recurrent infections (0.5), ataxia (3), 
telangiectasia (6) 
HIGM (3), AT (6) Unknown  Exon 54 c.7788G>A, 
IV564-2189 del 
16.kb (intron 63) 
Not noted  [20] 
L12 F  12 Respiratory 
failure 
Recurrent infections (1), ataxia (9), 
telangiectasia (9) 
HIGM (1), AT (9) Unknown  Unknown  Not noted  
L13 M  2 Post-
transplant-
lymhoprolifer
ative disorder 
No clinical features of AT HIGM phenotype disorder 
(primary immunodeficiency with 
unknown cause)(2), AT (post 
mortem) 
↑ Exon 12 
c.1316T>C/439 L>P, 
homozygous  
 
Not noted  [31] 
L14 F  8§   Ocular telangiectasia, motor and 
intellectual impairment (3) 
HIGM (2), AT (3) ↑ Exon 44, 
c.6198+1G>T, 
homozygous  
Healthy brother   [26] 
* Patients 1-5: Patients from the present cohort, numbers are in accordance with table 1; 
# Patients L1-L14: Patients from the literature search; 
§ Age at 1-11-2015, or age of death (not reported in the literature).  
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
26 
 
4. DISCUSSION  
This cohort study confirmed that classical AT patients have reduced survival compared to variant AT 
patients, although several classical AT patients survived beyond 30 years of age. The presence of a 
malignancy shortens the life expectancy of classical AT patients. Patients with AT-HIGM phenotype 
and patients with IgG2 deficiency had reduced survival compared to classical AT patients with normal 
IgG and IgG2 levels, respectively. The presence of ATM protein and IgA deficiency did not influence 
survival in classical AT patients in the present cohort.  
4.1. Variant AT and malignancies 
Some have suggested that the survival time of AT patients has not changed in the last 50 years[11]. 
However, classical AT patients surviving more than 30 years were rarely described in the past, 
whereas six patients in the present study reached this age. It is well-known that patients with 
classical AT have a shorter life expectancy of approximately 20 years[13, 34], mainly due to earlier 
onset of malignancies[35, 36], compared to variant AT patients. The results from the present study 
are in accordance with this literature, with a difference of 27 years in median age at diagnosis of 
malignancies. Classical AT patients without malignancies had a 2.5 times higher overall chance of 
survival compared to classical patients with a malignancy and their main cause of death was 
respiratory insufficiency, which is also in line with the available literature[11, 34].  We believe that 
respiratory diseases may contribute to severe complications of cancer treatment and a short survival 
time after cancer diagnosis in AT patients with malignancies.  
The 81% mortality rate due to malignancies among classical AT patients and the death of four out 
of five  variant AT patients with a malignancy are in accordance with the data of Micol et al., who 
described a mortality rate of 90% for hematological malignancies and 83.3% for carcinomas[11]. The 
median time of survival after diagnosis was less than one year for classical patients in both our and 
their cohort[11].  In our variant AT patients, the youngest age at diagnosis of cancer was 23 years. 
This late occurrence of malignancies is probably due to the residual kinase activity and normal 
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immunoglobulin levels protecting these patients from the development of lymphoid malignancies, 
especially in childhood[35, 36]. All patients without a malignancy in the variant group were still alive 
at the end of follow-up. Future studies need longer follow-up times to determine the final course of 
disease in variant AT patients.  
4.2. Immunology  
Immunodeficiency in general has been associated with an increased risk of cancer[35]. This study 
shows that malignancies were not more frequent in AT patients with IgA deficiency compared to 
those with normal IgA levels.  In contrast, malignancies were more common and the major cause of 
death in IgG2 deficient patients compared to patients with normal IgG2 levels. Respiratory failure was 
not the major cause of death in this group, although low IgG2 levels have been associated with a 
decreased polysaccharide antibody response, possibly causing increased susceptibility to respiratory 
tract infections[37]. This may be explained by the successful administration of antibiotic prophylaxis 
and immunoglobulin replacement therapy to these patients.  
The majority of classical AT patients had reduced levels of IgA but none of the variant AT patients 
were IgA deficient, which corresponds with the results of Staples et al.[9]. Based on similar 
percentages of patients with IgG2 or IgA deficiency in group 1b compared to group 2 and the 
variability in immunoglobulin levels between siblings (for example IgG2 levels in families 9 and 24 and 
45 and IgA levels in families 18, 20 and 24), it seems that the immune defects in AT do not correlate 
with detectability of the ATM protein.  
The AT-HIGM phenotype is caused by class-switch recombination deficiency and is characterized 
by decreased levels of serum IgG (and IgG subclasses) and IgA, with normal or increased levels of 
serum IgM[38]. Since recurrent sinopulmonary infections in patients with AT-HIGM manifest at a very 
young age, often before ataxia and telangiectasia are present or recognized, patients with HIGM are 
at risk of being misdiagnosed with ‘HIGM of undetermined cause’ instead of AT-HIGM[8, 20, 24-26].  
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The present study, as well as all available data from the literature, clearly revealed that HIGM 
strongly reduces the life expectancy in AT patients, with respiratory failure being a common cause of 
death. All seven patients in our cohort, and at least 10 out of 15 patients that were described earlier, 
died before the age of 15. Of all 22 patients with AT and HIGM described so far, no more than 5 
(23%) survived beyond adolescence. Despite intravenous immunoglobulin substitution therapy, the 
AT-HIGM patients in the present cohort developed respiratory insufficiency before the age of 15. This 
is a major point of interest since lung function is normal in most adolescents with AT [39].  
As immunoglobulin levels can vary during life, it may be difficult – especially retrospectively - to 
determine if a patient truly has or had HIGM. Patient 11 in our cohort was diagnosed with AT-HIGM 
at the age of 19 and survived with his immune deficiency until death at age 40. He had a low-normal 
IgG level at age 10 and he did not have recurrent infections during childhood (in contrast to all 
patients in group 1a). During adulthood, his IgG levels spontaneously increased to normal, although 
the IgG only consisted of IgG1. Therefore, we assume that he did not have HIGM during childhood 
and excluded him from group 1a (‘AT-HIGM’). The same holds true for patients 15b and 18a, who 
developed hypogammaglobulinemia in puberty. In addition, it may be questioned whether the two 
patients with AT and HIGM who survived beyond 15 years of age (patients L3 and L5, see Table 2), 
indeed had AT-HIGM. Patient L3, described by Soresina et al.[25] had an IgG deficiency with high IgM 
and normal IgA levels while suffering from proteinuria in early childhood, but normal IgA and IgG 
levels during immunoglobulin substitution therapy in November 2015. So her 
hypogammaglobulinemia may have been secondary to proteinuria. Patient L5’s immunoglobulin 
levels at the time of diagnosis were unavailable. Similar to the hypothesis regarding our patient 11 
(see above), she may have developed AT-HIGM later in life. 
In our cohort, patients with the same ATM mutations expressed different phenotypes for AT-
HIGM, even some that were siblings. This has also been described previously [25, 27, 30] (Table 2) 
and confirms that no correlation exists between ATM mutations and AT-HIGM phenotypes.  
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As AT is a severe disease, affecting - among others – the nervous system and the immune system, 
high-risk therapies targeting the underlying molecular aspects may be considered. This is illustrated 
by former administration of stem cell transplantation to patients with AT[31, 40, 41] and in patients 
with other neurodegenerative diseases[42] and primary immunodeficiencies[43]. Due to the poor 
prognosis of AT patients with HIGM, we believe that these patients are among the first eligible 
candidates to study the efficacy and safety of such therapies, as this group is expected to profit most 
from this therapy. Needless to say, no other accountable cause for the IgG deficiency should exist, 
and HIGM should be present since early childhood and not be a paraneoplastic feature. Since 
neonatal screening for severe primary immunodeficiency diseases is upcoming in some countries, 
patients may be diagnosed with AT before the first clinical symptoms emerge [44, 45]. The presence 
of HIGM in some of these young pre-symptomatic children can be used as a prognostic marker for a 
poor outcome. 
4.3. Strengths and limitations 
The strengths of this study are the large number of well-characterized AT patients, the inclusion of 
patients from different ethnicities, and the extensiveness of the data set. All but the Icelandic 
patients lived in the Netherlands and benefited from the National Health Care system. 
The present cohort contained many young children, but sensitivity analyses excluding patients 
with <10 years of follow-up did not lead to essential changes in results. As groups 1a and 4 included 
mainly female patients, adjustments for gender did affect some estimates, but not the interpretation 
of the results. While studying the Kaplan-Meier curves, for instance in Figure 2, one may erroneously 
assume that over 50% of variant AT patients survived beyond 50 years of age, and that 25% of 
classical AT patients survived beyond 40 years of age. As listed in Table 1 and in the table underneath 
Figure 2, however, only 5 out of 13 variant AT patients (38%) and 3 out of 48 classical AT patients 
(6%) survived beyond 50 and 40 years, respectively. The other 5 variant AT patients and 20 classical 
AT patients were still alive, but much younger at the time of study and were therefore censored in 
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the analysis. These large numbers of patients with relatively short follow-up times may lead to 
unrealistically positive cumulative probabilities of survival shown in the Kaplan-Meier curves.  
Given the rarity of AT,  this study includes a relatively large number of patients. Nevertheless, the 
main limitations of the study are due to small sample sizes, especially in subgroup analyses.  As a 
result, the data must be interpreted with caution and further investigations with larger cohorts of AT 
patients are needed to confirm our results. Fortunately, an international effort to register as many 
patients as possible is now ongoing. Exclusion of patients that were lost to follow-up, missing 
patients with a mild phenotype that were not diagnosed, publication bias, and unavailability of 
immunoglobulin levels may have caused selection and/or information bias, but the number of 
patients with missing data was small. Although this study spanned several decades and management 
of AT patients might have changed over the years, survival was not influenced by cohort effects of 
year of birth or diagnosis.  
5. CONCLUSION 
AT is known as a disease with a highly reduced life expectancy, but we described several patients 
with classical AT who survived longer than would be expected. On the other hand, this study is the 
first to show that IgG2 deficiency and HIGM negatively influence survival in AT patients, and to give 
an overview of all patients with AT and HIGM described in the literature. We believe that AT patients 
with HIGM are at extremely high risk of early death, and are therefore most eligible for future 
therapeutic trials.  
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Supplement 1: Clinical features of classical AT patients in group 3 
Patient Ataxia 
(age) 
Telangiec-
tasia (age) 
Wheelchair 
bound (age) 
Diagnosis 
AT (age) 
Serum 
AFP *  
Malignancy  Died 
(age) 
Additional 
features  
28  2 Not noted 13 5 - Lymphoma  17 Recurrent 
infections 
29  1 <6  Not noted 6 ↑ - - - 
30  1 <8 7 2 97 Lymphoma  9 Immunodeficiency  
31  1 <6 11 7 180 ALL 15 - 
32  2 Not noted 11 8 - Lymphoma  15 - 
33  1 <8 8 7 180 - - - 
34 2 <8 5 Not noted 102 - 10 Recurrent 
infections 
35a  2 <8 10 33 108 - - Diabetes, recurrent 
infections 
35b  2 10 Yes, age not 
noted 
33 40 - - Diabetes, recurrent 
infections 
36 3 <5 10 6 426 Lymphoma  17 Recurrent 
infections 
37 0.5 7 7 4 310 - - - 
38 1.5 4 
(minimal) 
- 3 110 - - Recurrent 
infections  
*in ug/l, normal <10 
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Supplement 2: Immunological parameters of patients from group 1a (AT-HIGM) 
Patient Age of 
blood test  
CD3 
(x109/L) 
CD4 
(x109/L) 
CD8 
(x109/L) 
CD19 
(x109/L) 
Naive CD4 
(x109/L) 
1 12 years 0.80 (L) 0.60 (N) 0.07 (L) 0.08 (L) 0.03 (L) 
2a 8 years 1.50 (N) 0.50 (L) 0.43 (N) 0.07 (L) 0.01 (L) 
2b 11 years 0.39 (L) 0.18 (L) 0.16 (L) 0.03 (L) 0.01 (L) 
2c - - - - - - 
3 2 years 0.35 (L) 0.22 (L) 0.26 (L) 0.08 (L) 0.04 (L) 
4 2 years 0.37 (L) 0.31 (L) 0.02 (L) 0.01 (L) 0.15 (L) 
5 11 years 0.65 (L) 0.31 (N) 0.31 (N) 0.01 (L) L 
L = below age-related normal value, N= normal age-related value. Reference values are based on the paper by Comans-Bitter et al.[18]. 
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Supplement 3: Hazard ratios (with 95% confidence intervals). 
 Classical AT  
versus variant 
AT (n=61) 
Group 1 versus 
group 2 (n=36) 
 
Malignancy versus 
no malignancy 
(n=61) 
IgG2 deficiency versus 
normal IgG2 (n=46) 
IgA deficiency versus 
normal IgA (n=53) 
AT-HIGM versus  
normal IgG  
Full cohort  1a versus 1b 
 HR 5.9 (2.0-17.7) 1.8 (0.7-4.4) 3.7 (1.7-8.1) 10.2 (2.3-45.0) 3.9 (1.7-9.3) 8.0 (1.6-40.1) 
 Gender adjusted 6.1 (2.0-18.7) 2.2 (0.9-5.7) 4.4 (1.9-9.9) 13.0 (2.9-58.7) 4.1 (1.7-9.9) 4.9 (0.9-25.4) 
 Exclusion < 10 yrs of follow-up 5.4 (1.8-16.4) 1.9 (0.7-5.4) 3.4 (1.5-7.8) 9.0 (2.0-40.5) 4.0 (1.6-10.2) 14.2 (1.6-127.7) 
 Gender adjusted and exclusion 
<10 yrs of follow-up 
5.3 (1.7 – 16.3) 2.4 (0.8-7.1) 3.5 (1.4-8.7) 11.1 (2.4-51.6) 4.1 (1.6-10.5 9.3 (1.0-88.5) 
HIGM excluded 1a versus 1b+2 
 HR 5.2 (1.7-16.1) 0.9 (0.3-3.0) 5.9 (2.2-15.7) 7.8 (1.7-36.2) 2.7 (1.0-7.1) 6.7 (2.2-20.7) 
 Gender adjusted 5.2 (1.7- 16.2) 1.3 (0.4-4.4) 6.7 (2.4-19.0) 9.2 (1.9-44.2) 2.6 (1.0-7.1) 5.2 (1.7-16.2) 
 Exclusion < 10 yrs of follow-up 4.8 (1.5-15.0) 0.9 (0.2-3.6) 4.8 (1.8-13.2) 7.0 (1.5-33.1) 2.8 (1.0-8.0) 12.9 (2.9-57.3) 
 Gender adjusted and exclusion 
<10 yrs of follow-up 
4.5 (1.4-14.3) 1.3 (0.3-5.3) 5.0 (1.7-14.7) 8.1 (1.6-40.5) 2.8 (1.0-8.0) 10.7 (2.4-48.9) 
Variants excluded 1a versus 
1b+2+3 
 HR x x 2.5 (1.1-5.5) 5.3 (1.2-23.5) 2.2 (0.9-5.1) 6.6 (2.3-18.8) 
 Gender adjusted x x 3.1 (1.3-7.0) 13.1 (2.6-66.8) 2.3 (1.0-5.5) 6.1 (2.1-17.7) 
 Exclusion < 10 yrs of follow-up x x 2.0 (0.8-4.9) 4.6 (1.0-20.9) 2.2 (0.9-5.4) 12.4 (3.1-48.9) 
 Gender adjusted and exclusion 
<10 yrs of follow-up 
x x 2.3 (0.9-5.9) 12.2 (2.2-66.0) 2.3 (0.9-5.7) 12.3 (3.1-49.4) 
AT-HIGM and variants excluded 1a versus 
1b+2+3+4 
 HR x x 3.6 (1.3-9.8) 4.0 (0.9-18.7) 1.4 (0.6-3.8) 9.2 (3.2-26.3) 
 Gender adjusted x x 4.2 (1.5-12.0) 10.9 (1.9-64.1) 1.5 (0.6-4.0) 9.5 (3.3-27.6) 
 Exclusion < 10 yrs of follow-up x x 2.6 (0.9-7.5) 3.6 (0.7-16.9) 1.5 (0.5-4.2) 17.8 (4.5-70.5) 
 Gender adjusted and exclusion 
<10 yrs of follow-up 
x x 3.0 (1.0-8.9) 11.5 (1.8-75.4) 1.6 (0.5-4.4) 19.9 (4.9-81.1) 
Group 1: patients without detectable ATM protein; group 1a: patients with AT-HIGM; group 1b: patients with normal IgG levels; group 2: patients with ATM protein and without ATM kinase activity 
group 3: patients with missing data on ATM protein and ATM kinase activity, but with clinical phenotypes similar to those in groups 1 and 2; group 4: patients with residual kinase activity (variant AT)  
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Supplement 4: Survival of AT patients without ATM protein (group 1) and with ATM protein without 
kinase activity (group 2)  
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Patients with  ATM protein without
kinase activity  (Group 2, n=19)
age
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%
 
 Years 0 10 20 30 40 
Without ATM 
protein 
At risk 17 12 5 2 1 
Deceased  0 5 9 11 12 
Censored * 0 0 3 4 4 
With ATM 
protein 
without ATM 
kinase activity 
At risk 19 13 10 2 0 
Deceased  0 3 4 9 9 
Censored * 0 3 5 8 10 
* Censored patients are patients that were alive in this age category at the end of follow-up. Differences in number of patients at risk can 
be explained by deaths and censored patients. Deceased and censored numbers are cumulative. 
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Supplement 5: Time of survival after cancer diagnosis for classical and variant AT patients 
 Patient Age of 
diagnosis of 
cancer (years) 
Age of death 
(years) 
Time of survival after 
cancer diagnosis 
(years) 
Classical  1 12 13 1 
2c 10 10 <1 
4 9 9 <1 
7 17 22 4.5 
8 9 9 <1 
9b 10 10 <1 
11 39 40 1 
13 52 54 2 
15a 8 9 1 
15b 25 26 <1 
17b 4 4 <1 
18b 10 10 <1 
19 27 27 <1 
23a 24 24 <1*  
23b 15 - - 
28 16 17 1* 
30 8 9 1 
31 15 15 <1 
32 15 15 <1 
33 18  -  - 
36 16 17 1 
Variant 40 (42 and) 46 47 (5 and) <1 
41 32 -  - 
44b 23 23 <1 
47a >45 48 <3 
47c 51 51 <1 
* Cause of death was unknown. 
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Supplement 6: Survival of classical AT patients (AT-HIGM excluded) with IgA deficiency and patients 
with normal IgA levels 
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0
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100
Classical  AT patients with
IgA deficiency (n=18)
Classical AT patients with
normal  IgA levels (n=19)
age
c
u
m
u
la
ti
v
e
 s
u
r
v
iv
a
l 
%
 
  Years 0 10 20 30 40 50 
Classical 
without 
AT-HIGM 
IgA 
deficiency 
At risk 18 12 6 2 0  
Deceased  0 3 5 7 8  
Censored * 0 3 7 9 10  
Normal IgA At risk 19 15 10 4 3 1 
 Deceased  0 2 5 9 9 9 
  Censored * 0 2 4 6 7 9 
* Censored patients are patients that were alive in this age category at the end of follow-up. Differences in number of patients at risk can 
be explained by deaths and censored patients. Deceased and censored numbers are cumulative. 
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